Micafungin: a therapeutic review
Abstract
In recent decades, the incidence of aspergillosis, candidiasis and clinically important deep mycoses has been increasing, with advances in transplantation medicine and anticancer chemotherapy. Micafungin (FK463, Fujisawa Healthcare) has been developed as a novel type of antifungal agent, which inhibits 1,3-beta-D-glucan synthase in the fungal cell wall. Micafungin, one of the echinocandins, exhibits extremely high antifungal activity against Aspergillus spp. and Candida spp. in vitro. It is also characterized by a linear pharmacokinetic profile and a much lower prevalence of adverse reactions than amphotericin B. Micafungin is quite useful in the treatment of deep mycoses. In clinical studies in Japan, micafungin was found to be highly effective against aspergillosis (57.1% overall efficacy rate) and candidiasis (78.6%). Micafungin is expected to increase the efficacy rate of treatment in patients with severe aspergillosis or candidiasis when used in combination with amphotericin B or mold azoles.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The resistance of Candida glabrata to micafungin might be higher in Japan than in other countries because micafungin is more frequently prescribed in Japan.
“The resistance of C. glabrata to MCFG might be higher in Japan than in other countries because MCFG, which was developed in Japan,28 is more frequently prescribed in Japan.”
Cites
Petraitis, V., Petraitienė, R., Sarafandi, A. A., Kelaher, A. M., Lyman, C. A., Casler, H. E., Sein, T., Groll, A. H., Bacher, J. D., Avila, N. A., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/375420 · Cited by 233 · see citing works
Fungal infections in the recipients of solid organ transplantation
Singh, N. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00067-3 · Cited by 202 · see citing works
Kohno, S., Masaoka, T., Yamaguchi, H., Mori, T., Urabe, A., Ito, A., Niki, Y., & IKEMOTO, H. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410020406 · Cited by 152 · see citing works
Yamazaki, T., Kume, H., MURASE, S., Yamashita, E., & Arisawa, M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1732-1738.1999 · Cited by 118 · see citing works
IWAMOTO, T., Fujie, A., Sakamoto, K., TSURUMI, Y., Shigematsu, N., Yamashita, M., HASHIMOTO, S., OKUHARA, M., & KOHSAKA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.1084 · Cited by 111 · see citing works
FK463, a Novel Water-soluble Echinocandin Lipopeptide. Synthesis and Antifungal Activity.
Tomishima, M., Ohki, H., Yamada, A., Takasugi, H., Maki, K., Tawara, S., & Tanaka, H. (1999) · The Journal of Antibiotics · doi:10.7164/antibiotics.52.674 · Cited by 107 · see citing works
In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide
Mikamo, H. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.485 · Cited by 100 · see citing works
Antifungal Mechanism of FK463 against Candida albicans and Aspergillus fumigatus.
HATANO, K., MORISHITA, Y., Nakai, T., & Ikeda, F. (2002) · The Journal of Antibiotics · doi:10.7164/antibiotics.55.219 · Cited by 77 · see citing works
Beaulieu, D., TANG, J., Yan, S.-C. B., Vessels, J. M., Radding, J. A., & Parr, T. R. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.5.937 · Cited by 20 · see citing works
Deep‐seated mycosis as a complication in bone marrow transplantation patients
Wakayama, M., Shibuya, K., Ando, T., Oharaseki, T., Takahashi, K., Naoe, S., & Coulson, W. F. (2002) · Mycoses · doi:10.1046/j.1439-0507.2002.00753.x · Cited by 18 · see citing works
Drug interactions of micafungin in vitro
Kaneko, H., Yamato, Y., Hashimoto, T., Ishii, I., Shiraga, T., Kawamura, A., Terakawa, M., & Kagayama, A. (2002) · Medical Entomology and Zoology · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · see citing works
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 399 · see citing works
An update on antifungal targets and mechanisms of resistance in<i>Candida</i><i>albicans</i>
Akins, R. A. (2005) · Medical Mycology · doi:10.1080/13693780500138971 · Cited by 291 · see citing works
Denning, D. W., Marr, K. A., Lau, W. M., Facklam, D., Ratanatharathorn, V., Becker, C., Ullmann, A. J., Seibel, N. L., Flynn, P. M., van Burik, J. H., et al. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.03.003 · Cited by 293 · see citing works
Clinical Pharmacokinetics of Systemically Administered Antimycotics
Bellmann, R. (2007) · Current Clinical Pharmacology · doi:10.2174/157488407779422311 · Cited by 84 · see citing works
Ajesh, K., & Sreejith, K. (2009) · Peptides · doi:10.1016/j.peptides.2009.01.026 · Cited by 69 · see citing works
Liposomal amphotericin B: clinical experience and perspectives
Gibbs, W. J., Drew, R. H., & Perfect, J. R. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.2.167 · Cited by 60 · see citing works
Next-Generation Sequencing Applications for the Study of Fungal Pathogens
Jiang, S., Chen, Y., Han, S., Lv, L., & Li, L. (2022) · Microorganisms · doi:10.3390/microorganisms10101882 · Cited by 56 · see citing works
Echinocandins in the management of invasive fungal infections, part 2
Morris, M. I., & Villmann, M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050464.p2 · Cited by 54 · see citing works
Okugawa, S., Ota, Y., Tatsuno, K., Tsukada, K., Kishino, S., & Koike, K. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540600951333 · Cited by 48 · see citing works
Echinocandins: role in antifungal therapy, 2005
Zaas, A. K., & Alexander, B. D. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.10.1657 · Cited by 45 · see citing works
Antifúngicos sistémicos. Farmacodinamia y farmacocinética
Catalán, M., & Montejo, J. C. (2006) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(06)70012-2 · Cited by 42 · see citing works
Helmy, N. M., & Parang, K. (2023) · Pharmaceuticals · doi:10.3390/ph16060892 · Cited by 39 · see citing works
Ichikawa, S., & Matsuda, A. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.5.487 · Cited by 35 · see citing works
Micafungin-Induced Suicidal Erythrocyte Death
Peter, T., Bissinger, R., Signoretto, E., Mack, A. F., & Lang, F. J. W. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445650 · Cited by 34 · see citing works
Kajihara, T., Yahara, K., Nagi, M., Kitamura, N., Hirabayashi, A., Hosaka, Y., Abe, M., Miyazaki, Y., & Sugai, M. (2022) · Medical Mycology · doi:10.1093/mmy/myac071 · Cited by 29 · see citing works
FR209602 and Related Compounds, Novel Antifungal Lipopeptides from Coleophoma crateriformis No. 738
Kanasaki, R., Sakamoto, K., Hashimoto, M., Takase, S., TSURUMI, Y., Fujie, A., Hino, M., Hashimoto, S., & Hori, Y. (2006) · The Journal of Antibiotics · doi:10.1038/ja.2006.20 · Cited by 29 · see citing works
Kanasaki, R., Kobayashi, M., Fujine, K., Sato, I., Hashimoto, M., Takase, S., TSURUMI, Y., Fujie, A., Hino, M., Hashimoto, S., et al. (2006) · The Journal of Antibiotics · doi:10.1038/ja.2006.23 · Cited by 27 · see citing works
Micafungin: the US perspective
Zaas, A. K., & Steinbach, W. J. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.2.183 · Cited by 21 · see citing works
Fujita, M., Ouchi, H., Harada, E., Ikegame, S., Nakanishi, Y., Fujita, M., Matsumoto, T., Uchino, J., Watanabe, K., Tao, Y., et al. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0391-x · Cited by 19 · see citing works
Yeast and Fungal Polysaccharides
Ohno, N. (2007) · Elsevier eBooks · doi:10.1016/b978-044451967-2/00132-x · Cited by 16 · see citing works
Biological Properties and Analytical Methods for Micafungin: A Critical Review
Marena, G. D., Ramos, M. A. D. S., Bauab, T. M., & Chorilli, M. (2020) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2020.1726726 · Cited by 14 · see citing works
KB425796-A, a novel antifungal antibiotic produced by Paenibacillus sp. 530603
Kai, H., YAMASHITA, M., Takase, S., Hashimoto, M., Muramatsu, H., Nakamura, I., Yoshikawa, K., Ezaki, M., Nitta, K., Watanabe, M., et al. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.63 · Cited by 12 · see citing works
DETECTION OF ASPERGILLUS SPP. IN BIOLOGICAL SAMPLES BY REAL-TIME PCR
Bolehovská, R., Plíšková, L., Buchta, V., Cerman, J., & Hamal, P. (2006) · Biomedical Papers · doi:10.5507/bp.2006.035 · Cited by 12 · see citing works
Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans
Akins, R. A., & Sobel, J. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_29 · Cited by 12 · see citing works
FR209602 and Related Compounds, Novel Antifungal Lipopeptides from Coleophoma crateriformis No. 738
Kanasaki, R., Abe, F., Furukawa, S., Yoshikawa, K., Fujie, A., Hino, M., Hashimoto, S., & Hori, Y. (2006) · The Journal of Antibiotics · doi:10.1038/ja.2006.21 · Cited by 11 · see citing works
Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans
Akins, R. A., & Sobel, J. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_30 · Cited by 9 · see citing works
Soni, N., & Wagstaff, A. (2005) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2005.11.010 · Cited by 8 · see citing works
In Vitro Susceptibilities to Caspofungin and Micafungin of Clinical Isolates of Candida Species
Choi, H. W., Shin, J. H., Lee, J. S., Cho, D., Shin, M. G., Suh, S., & Ryang, D. W. (2006) · Annals of Laboratory Medicine · doi:10.3343/kjlm.2006.26.4.275 · Cited by 6 · see citing works
Arzneimittelinteraktionen in der Intensivmedizin
Drust, A. (2020) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-0903-1767 · Cited by 3 · see citing works
Interactions médicamenteuses des antifongiques systémiques
Delaunay, P., & Fissore, C. (2006) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2006.06.002 · Cited by 2 · see citing works
Analysis of Micafungin in Serum by Capillary Zone Electrophoresis
Kitahashi, T., & Furuta, I. (2007) · Journal of Chromatographic Science · doi:10.1093/chromsci/45.1.28 · Cited by 1 · see citing works
Arzneimittelinteraktionen in der Intensivmedizin
Drust, A. (2020) · Intensivmedizin up2date · doi:10.1055/a-1153-2110 · Cited by 1 · see citing works
Ohno, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00010-9
- Authors
- Higashiyama, Y., & Kohno, S.
- Affiliations
- Nagasaki University (JP)
- Venue
- Expert Review of Anti-infective Therapy
- Publisher
- Informa UK Limited
- Published
- 2004-06
- Volume
- 2
- Issue
- 3
- Pages
- 345-355
- ISSN
- 1478-7210 (ISSN-L)
- 1744-8336
- OpenAlex
- W2105523705
- Cited by
- 34
- References
- 11
- Citations by year
- 2023: 1 · 2022: 2 · 2020: 4 · 2017: 2 · 2016: 1 · 2013: 1 · 2012: 1
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Anti-infective Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- micafungin, echinocandins, aspergillosis, candidiasis, systemic fungal infection, antifungal agents, pharmacokinetics, adverse effects, amphotericin B, combination therapy, Aspergillus, Candida
- MeSH terms
- Micafungin, Animals, Antifungal Agents, Aspergillosis, Candidiasis, Oral, Child, Clinical Trials as Topic, Drug Interactions, Fungi, Humans, Lipoproteins, Mycoses, Peptides, Cyclic, HIV Infections, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
